JP2019529541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529541A5 JP2019529541A5 JP2019535191A JP2019535191A JP2019529541A5 JP 2019529541 A5 JP2019529541 A5 JP 2019529541A5 JP 2019535191 A JP2019535191 A JP 2019535191A JP 2019535191 A JP2019535191 A JP 2019535191A JP 2019529541 A5 JP2019529541 A5 JP 2019529541A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- composition
- additional therapeutic
- kit
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 210000003630 histaminocyte Anatomy 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 230000000087 stabilizing effect Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 14
- 230000009385 viral infection Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- IYSYPCSSDZBWHN-UHFFFAOYSA-N Nor-ketotifen Chemical compound C1=2C=CSC=2C(=O)CC2=CC=CC=C2C1=C1CCNCC1 IYSYPCSSDZBWHN-UHFFFAOYSA-N 0.000 claims description 7
- 239000003443 antiviral agent Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 206010037660 Pyrexia Diseases 0.000 claims description 5
- 230000001754 anti-pyretic effect Effects 0.000 claims description 2
- 239000002221 antipyretic Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 7
- 206010022000 influenza Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical group CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 3
- 229960003752 oseltamivir Drugs 0.000 claims 3
- 206010050685 Cytokine storm Diseases 0.000 claims 2
- 206010052015 cytokine release syndrome Diseases 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010022004 Influenza like illness Diseases 0.000 claims 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960004958 ketotifen Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385021P | 2016-09-08 | 2016-09-08 | |
| US62/385,021 | 2016-09-08 | ||
| PCT/US2017/050409 WO2018048989A1 (en) | 2016-09-08 | 2017-09-07 | Mast cell stabilizers for treatment of hypercytokinemia and viral infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529541A JP2019529541A (ja) | 2019-10-17 |
| JP2019529541A5 true JP2019529541A5 (enExample) | 2020-10-08 |
Family
ID=61281984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019535191A Pending JP2019529541A (ja) | 2016-09-08 | 2017-09-07 | 高サイトカイン血症及びウィルス感染の処置の為の肥満細胞安定剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10501527B2 (enExample) |
| EP (1) | EP3509596B1 (enExample) |
| JP (1) | JP2019529541A (enExample) |
| KR (1) | KR20190073365A (enExample) |
| CN (1) | CN109952101A (enExample) |
| AU (2) | AU2017325010A1 (enExample) |
| BR (1) | BR112019004496A2 (enExample) |
| CA (1) | CA3036230A1 (enExample) |
| ES (1) | ES2988617T3 (enExample) |
| IL (1) | IL265208A (enExample) |
| MX (1) | MX389999B (enExample) |
| MY (1) | MY204310A (enExample) |
| PH (1) | PH12019500513A1 (enExample) |
| RU (1) | RU2760682C2 (enExample) |
| WO (1) | WO2018048989A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| CN116889562A (zh) | 2016-08-31 | 2023-10-17 | 通用医疗公司 | 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞 |
| CA3036230A1 (en) * | 2016-09-08 | 2018-03-15 | Emergo Therapeutics, Inc. | Mast cell stabilizers for treatment of hypercytokinemia and viral infection |
| WO2018075574A1 (en) | 2016-10-18 | 2018-04-26 | Emergo Therapeutics, Inc. | Mast cell stabilizers for treatment of chronic inflammatory conditions |
| AU2019336698A1 (en) * | 2018-09-05 | 2021-03-25 | Aztherapies, Inc. | Methods of treating cytokine release syndrome |
| KR20210113610A (ko) | 2018-12-10 | 2021-09-16 | 더 제너럴 하스피탈 코포레이션 | 크로몰린 에스테르 및 이의 용도 |
| US20200268734A1 (en) * | 2019-02-22 | 2020-08-27 | Bridge Pharma, Inc. | Methods of treatment of respiratory disorders |
| US10959992B2 (en) | 2019-02-22 | 2021-03-30 | Bridge Pharma Inc. | Methods of treatment of asthma and COPD |
| WO2021178395A1 (en) * | 2020-03-06 | 2021-09-10 | Figene, Llc | Fibroblast and tlr activated fibroblast treatment of viral induced acute respiratory distress syndrome |
| US12458622B2 (en) | 2020-04-06 | 2025-11-04 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
| US20230000852A1 (en) * | 2021-06-29 | 2023-01-05 | Bridge Pharma, Inc. | Treatment of Dermal Cytokine Storm Syndromes |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6878715B1 (en) | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
| WO1998035677A1 (en) | 1997-02-18 | 1998-08-20 | Bridge Pharma, Inc. | Non-sedating histamine antagonist compounds, compositions and methods of use thereof |
| JP2001519789A (ja) | 1997-04-03 | 2001-10-23 | ブリッジ ファーマ，インコーポレーテッド | ベンゾシクロヘプタチオフェン化合物 |
| EP1014979A4 (en) | 1997-06-09 | 2003-08-20 | Bridge Pharma Inc | CONNECTIONS WITH COMBINED ANTIHISTAMINIC AND FAST-CELL STABILIZING ACTIVITY FOR OPHTHALMOLOGICAL USE |
| CA2283603A1 (en) | 1998-10-01 | 2000-04-01 | Paul W. Behnke | Forced closed-loop cooling for a submersible pump motor |
| HUP0202671A3 (en) | 1999-09-13 | 2005-01-28 | Bridge Pharma Inc Sarasota | Optically active isomers of ketotifen and therapeutically active metabolites thereof |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20050249735A1 (en) | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20030118670A1 (en) * | 2001-07-11 | 2003-06-26 | Smith C. Steven | Novel composition and method for altering allergenic protein in the environment |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| US20060084695A1 (en) | 2004-04-29 | 2006-04-20 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| WO2007084253A2 (en) | 2005-11-28 | 2007-07-26 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| SG177934A1 (en) | 2006-09-29 | 2012-02-28 | Johnson & Johnson Vision Care | Methods and ophthalmic devices used in the treatment of ocular allergies |
| US20080139531A1 (en) | 2006-12-04 | 2008-06-12 | Alcon Manufacturing Ltd. | Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair |
| US20100166804A1 (en) * | 2007-05-23 | 2010-07-01 | Dennis Penn | Methods |
| WO2009050203A1 (en) | 2007-10-15 | 2009-04-23 | Revolymer Limited | Solvent-free synthesis of amphiphilic polymeric material |
| EP2234329A4 (en) | 2007-12-24 | 2012-11-21 | Zte Corp | METHOD AND SYSTEM FOR PROTECTING THE SHARED CHANNEL IN THE OPTICAL TRANSMISSION SYSTEM |
| BRPI0822221A2 (pt) * | 2008-01-04 | 2015-06-23 | Alcon Pharmaceuticals Ltd | Composições aquosas e estáveis de ciclosporina |
| WO2009142772A2 (en) | 2008-05-23 | 2009-11-26 | Mastcell Pharmaceuticals, Inc. | Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
| US8741930B2 (en) | 2008-10-24 | 2014-06-03 | Bridge Pharma, Inc. | Treating xerophthalmia with norketotifen |
| WO2010059894A1 (en) | 2008-11-21 | 2010-05-27 | Bridge Pharma, Inc. | Ocular formulations of norketotifen |
| US20120058984A1 (en) | 2009-03-17 | 2012-03-08 | Catherine Mary Alder | Pyrimidine derivatives used as itk inhibitors |
| JP2012520880A (ja) * | 2009-03-17 | 2012-09-10 | アーシエックス セラピューティックス， インコーポレイテッド | ケトチフェンの眼科用製剤および使用方法 |
| US20110294897A1 (en) | 2009-12-02 | 2011-12-01 | Bridge Pharma, Inc. | Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion |
| AU2011252883B2 (en) | 2010-05-14 | 2015-09-10 | Abbvie Inc. | IL-1 binding proteins |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| HK1198328A1 (zh) | 2011-07-13 | 2015-04-02 | Abbvie Inc. | 使用抗il-13抗體治療哮喘的方法和組合物 |
| WO2014040112A1 (en) | 2012-09-17 | 2014-03-20 | Guina Research & Development Pty Ltd | Electromagnetic turbine |
| US8557846B1 (en) | 2012-10-23 | 2013-10-15 | Bridge Pharma, Inc. | Medicinal treatment of dermal diseases in dogs |
| US8778971B2 (en) | 2012-10-23 | 2014-07-15 | Bridge Pharma, Inc. | Medicinal treatment of dermal diseases in companion animals |
| US20140120121A1 (en) | 2012-10-30 | 2014-05-01 | Bridge Pharma, Inc. | Medicinal treatment of atopic inflammatory diseases |
| US20150272941A1 (en) | 2012-10-30 | 2015-10-01 | Bridge Pharma, Inc. | Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen |
| US9347325B2 (en) | 2012-10-31 | 2016-05-24 | Solar Turbines Incorporated | Damper for a turbine rotor assembly |
| JP6084473B2 (ja) | 2013-02-01 | 2017-02-22 | 日立オートモティブシステムズ株式会社 | 複合センサ |
| US9345697B2 (en) | 2013-08-06 | 2016-05-24 | Bridge Pharma, Inc. | Methods of treatment of non-histaminic pruritus |
| US9138431B2 (en) * | 2013-08-06 | 2015-09-22 | Bridge Pharma, Inc. | Methods of treatment of histamine H-4 receptor-related pruritus |
| US9439895B2 (en) | 2013-08-06 | 2016-09-13 | Bridge Pharma, Inc. | Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients |
| US9962363B2 (en) | 2014-02-10 | 2018-05-08 | Patara Pharma, LLC | Mast cell stabilizers treatment for systemic disorders |
| CA2976369A1 (en) | 2015-02-13 | 2016-08-18 | Yale University | Biaryltriazole inhibitors of macrophage migration inhibitory factor |
| US10293352B2 (en) | 2015-02-13 | 2019-05-21 | Kärcher North America, Inc. | Hand held fluid dispensing apparatus |
| WO2017035418A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for treatment of immune and inflammatory disorders |
| US9694003B2 (en) | 2015-10-15 | 2017-07-04 | Bridge Pharma, Inc. | Formulations and methods for treating high intraocular pressure |
| CA3036230A1 (en) | 2016-09-08 | 2018-03-15 | Emergo Therapeutics, Inc. | Mast cell stabilizers for treatment of hypercytokinemia and viral infection |
| WO2018075574A1 (en) | 2016-10-18 | 2018-04-26 | Emergo Therapeutics, Inc. | Mast cell stabilizers for treatment of chronic inflammatory conditions |
-
2017
- 2017-09-07 CA CA3036230A patent/CA3036230A1/en active Pending
- 2017-09-07 WO PCT/US2017/050409 patent/WO2018048989A1/en not_active Ceased
- 2017-09-07 BR BR112019004496A patent/BR112019004496A2/pt not_active Application Discontinuation
- 2017-09-07 JP JP2019535191A patent/JP2019529541A/ja active Pending
- 2017-09-07 AU AU2017325010A patent/AU2017325010A1/en not_active Abandoned
- 2017-09-07 US US15/697,835 patent/US10501527B2/en active Active
- 2017-09-07 CN CN201780068796.6A patent/CN109952101A/zh active Pending
- 2017-09-07 EP EP17849505.7A patent/EP3509596B1/en active Active
- 2017-09-07 MX MX2019002781A patent/MX389999B/es unknown
- 2017-09-07 KR KR1020197010083A patent/KR20190073365A/ko not_active Ceased
- 2017-09-07 ES ES17849505T patent/ES2988617T3/es active Active
- 2017-09-07 MY MYPI2019000588A patent/MY204310A/en unknown
- 2017-09-07 RU RU2019110150A patent/RU2760682C2/ru active
- 2017-11-17 US US15/816,461 patent/US10160796B2/en active Active
-
2018
- 2018-11-15 US US16/192,385 patent/US10494420B2/en active Active
-
2019
- 2019-03-07 IL IL265208A patent/IL265208A/en unknown
- 2019-03-08 PH PH12019500513A patent/PH12019500513A1/en unknown
- 2019-10-25 US US16/664,039 patent/US11072648B2/en active Active
- 2019-10-25 US US16/664,037 patent/US10787502B2/en active Active
-
2023
- 2023-06-23 AU AU2023204000A patent/AU2023204000A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529541A5 (enExample) | ||
| RU2019110150A (ru) | Стабилизаторы тучных клеток лечения гиперцитокинемии и вирусной инфекции | |
| JP2023002662A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2017526716A5 (enExample) | ||
| JP2018193377A5 (enExample) | ||
| JP2018048154A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2009535352A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2018513188A5 (enExample) | ||
| JP2012517449A5 (enExample) | ||
| JP2019510079A5 (enExample) | ||
| JP2013500977A5 (enExample) | ||
| JP2013509441A5 (enExample) | ||
| JP2016027060A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2018172440A5 (enExample) | ||
| JP2017522300A5 (enExample) | ||
| JP2016537338A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| JP2017515840A5 (enExample) |